TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02561689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealing
Description: Procedure:~* The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~* Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~* The occlusal surface is sealed by the dentist or dental hygienist.~* Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealing
Description: Procedure:~* The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~* Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~* The occlusal surface is sealed by the dentist or dental hygienist.~* Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years
Study: NCT02547064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glidescope guided intubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope guided intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope®
Study: NCT03169127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
Study: NCT00028496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox GM-CSF vaccine adjuvant
Description: Given intradermally
Study: NCT00976989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC
Description: 5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC
Description: 5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 for the first dose; 100 mg/m\^2 if no dose limiting toxicity occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 for the first dose; 100 mg/m\^2 if no dose limiting toxicity occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCH
Description: Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m\^2. All treatments were given every three weeks by the IV route.
Study: NCT02491333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: true acupuncture
Description: True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham acupuncture
Description: Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin will be given at 0.5g/times, 3 times one day and for 4 month.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo metformin
Description: Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo metformin
Description: Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
Study: NCT01488695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope Groove
Description: GlideScope Groove

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control: Macintosh blade
Description: Control: Patients will be intubated using the Macintosh blade
Study: NCT02681549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Bevacizumab
Description: Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
Study: NCT04217941

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Health education with practical demonstration of nasal ointment
Description: Health education with practical demonstration of medicine was compared to health education without practical demonstration

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Health education with practical demonstration of nasal ointment
Description: Health education with practical demonstration of medicine was compared to health education without practical demonstration
Study: NCT02478099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: Anti-PD-L1 antibody
Study: NCT03852719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via SC injections
Study: NCT04104776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: CPI-0209 alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: CPI-0209 alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: CPI-0209 alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: CPI-0209 alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: CPI-0209 alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: CPI-0209 alone
Study: NCT03308708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Description: Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
Study: NCT00346788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical approach for total knee arthroplasty
Description: total knee arthroplasty surgery using minimally invasive surgery or standard technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical approach for total knee arthroplasty
Description: total knee arthroplasty surgery using minimally invasive surgery or standard technique.
Study: NCT02732548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy (NPWT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRODERM Application(s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
Study: NCT00834262

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Intervention type: DRUG
Intervention: biphasic insulin aspart 50
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Intervention type: DRUG
Intervention: biphasic insulin aspart 70
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT02595619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RRT plus ECCO2R
Description: Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
Study: NCT01158781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: gait, balance, arm function, cognition
Description: 12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
Study: NCT03779698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiodentineTM
Description: In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BiodentineTM
Description: In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formocresol
Description: In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
Study: NCT04661982

Intervention type: OTHER
Intervention: Long-term Follow-up
Description: Undergo long term follow-up

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01190501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: complier device
Description: The procedure of use of complier has to follow the recommendations for standardization of subject conditions.~Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites.
Study: NCT02094651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium
Description: The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an inactive substance that looks like the active drug.
Study: NCT03036020

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CereTom Neurologica Samsung
Description: Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
Study: NCT00933998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)
Description: One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
Study: NCT04187495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01
Description: Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.~For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).
Study: NCT00271102

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior vaginal repair (colporrhaphy)
Description: vaginal repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior vaginal repair (colporrhaphy)
Description: vaginal repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal paravaginal defect repair
Description: abdominal repair
Study: NCT04106310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theranova dialyzer
Description: a middle cut-off dialyzer
Study: NCT02212821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: physiological saline
Study: NCT02563028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SightSaver Visual Stimulator
Description: Evoked response photic stimulator
Study: NCT03669445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 21-day cycles induction and 28-day cycles consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 21-day cycles induction and 28-day cycles consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 21-day cycles induction and 28-day cycles consolidation
Study: NCT03437122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
Study: NCT04489706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide for injection
Description: Arsenic trioxide for injection, 0.16 mg/kg (maximum single dose is 10 mg), daily IV drip, d1 to d14, once every 28 days, for six cycles of treatment or until one of the following events occurs: Initiation of new anti-tumor therapy, disease progression, withdrawal of Informed consent form (ICF) and/or death.
Study: NCT04217941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Health Education and practical demonstration of Nasal spray and intranasal ointment
Description: We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
Study: NCT01147185

Intervention type: DEVICE
Group type: OTHER
Intervention: Locomotor training using a robotic device
Description: 50min walking time, 3-5 trainings/week.
Study: NCT03933735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNB-383B
Description: Intravenous (IV) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNB-383B
Description: Intravenous (IV) Injection
Study: NCT01147185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training using a robotic device
Description: 25min walking time, 3-5 trainings/week.
Study: NCT04338464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial therapy for South Asian women experiencing mood disorders
Description: The 12 week intervention has four major components:~* Relational theory (Belgrave, 2002) \& South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~* Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek \& Ehrenriech-May, 2012; Ritschel, Noriel \& Lindsay, 2015).~* Psychoeducation on mental health, sexual health, and substance use.~* Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support.
Study: NCT04939285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
Study: NCT00006095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT05685446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice water
Description: Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
Study: NCT00645606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab :500 mg/m² every 8 weeks during 2 years
Study: NCT00229931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: 4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
Study: NCT01387061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic resection
Description: surgical resection of the liver for multiple HCC
Study: NCT01858402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: 15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
Study: NCT01411124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin enacarbil
Description: 600 mg investigational compound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diphenhydramine
Description: 50 mg active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04370808

Intervention type: OTHER
Intervention: Exposure
Description: Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.

Intervention type: OTHER
Intervention: Exposure
Description: Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
Study: NCT00271102

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal paravaginal defect repair
Description: abdominal repair
Study: NCT02226718

Intervention type: OTHER
Intervention: Administration of questionnaire
Study: NCT02664974

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported.
Study: NCT03556202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC